A biotechnology company building personalized cancer vaccines called DCVax that use a patient's own immune cells to target their tumor, rather than a one-size-fits-all drug. Its lead product, DCVax-L, is being developed for glioblastoma, an aggressive brain cancer. The company was founded in 1996 by Dr. Alton Boynton, a scientist from Seattle's Pacific Northwest, the region that inspired its name; he had earlier led research at the Pacific Northwest Research Foundation that later gave rise to the Fred Hutchinson Cancer Center.
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +7.51M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.